DNTH earnings analysis
What we found in DNTH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Dianthus remains a pre-revenue, clinical-stage company: Q2 2026 license revenue rose to $0.8 million, but the net loss widened to $50.2 million as R&D increased to $48.7 million to support claseprubart and new pipeline programs. Operating margin improved mechanically versus the tiny Q2 2025 revenue base, to approximately -7,685.3%, but deteriorated versus Q1 as operating loss rose to $61.5 million. The central positives are a 75% CIDP interim response rate and approximately $1.2 billion of liquidity projected to fund operations into 2030; the tradeoff is accelerating clinical cash burn and likely future dilution.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- License revenue increased year over year
- Q2 license revenue was $0.8 million, up $0.6 million from $0.2 million in Q2 2025 and up $0.3 million from $0.5 million in Q1 2026, driven by reimbursable costs associated with ongoing claseprubart trials.
- CIDP interim response exceeded target
- CAPTIVATE's first 40 Part A completers produced a 75% CIDP response rate, above the stated target of 50% or greater. The company achieved 20 confirmed responders before all 40 participants had completed Part A.
- CAPTIVATE design reduced planned enrollment
- The CIDP program reduced planned Part A enrollment to up to 256 patients from up to 480 and planned Part B randomization to 128 patients from 192 following the interim responder analysis.
- Liquidity runway extends into 2030
- Cash, cash equivalents and investments were approximately $1.2 billion at June 30, 2026; management believes this balance funds the operating plan into 2030.
- Financing materially strengthened liquidity
- Net financing cash inflow was $749.8 million in the first six months of 2026, principally including $676.1 million of public-offering proceeds and $58.7 million from the ATM program.
- Multiple clinical catalysts are scheduled
- MoMeNtum enrollment exceeded its 36-patient target, with top-line data from 46 patients expected in December 2026; EMERGE Phase 3 enrolled approximately 195 planned gMG participants and is targeted for 2H 2028 top-line results.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and operating spend accelerated
- Q2 net loss widened to $50.2 million from $31.6 million in Q2 2025, while loss from operations expanded to $61.5 million from $34.9 million. Diluted EPS of -$0.90 worsened from -$0.85 in Q1 2026 and -$0.88 a year earlier.
- Late-stage trial spending is increasing
- R&D expense increased $22.4 million year over year to $48.7 million in Q2, including a $13.0 million increase in claseprubart-related expense. Management expects R&D expense to increase substantially as programs move into larger and later-stage trials.
- Operating cash burn increased 51%
- Operating cash use was $77.8 million in the first six months of 2026, versus $51.5 million in the prior-year period; capital expenditures were only $0.2 million, so cash burn is principally clinical and operating rather than fixed-asset driven.
- Future financing could dilute shareholders
- The company used its entire $200.0 million ATM capacity, selling 3,632,534 shares, and states it will need additional capital to complete development and potential commercialization. It had an accumulated deficit of $427.8 million at June 30, 2026.
- No explicit risk-factor update; sizable commitments
- The filing does not identify newly added or revised Item 1A risk factors versus the March 2026 10-K; it incorporates prior risks by reference. Nevertheless, DNTH212 commitments include up to $962.0 million in development, regulatory and sales milestones, in addition to $30.0 million already paid as of June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.9
- Gross margin
- 100%
- Operating margin
- -7685.3%
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q. Management maintained its view that approximately $1.2 billion of cash, cash equivalents and investments at June 30, 2026 should fund operations into 2030. Milestones expected are MoMeNtum top-line data in December 2026, CAPTIVATE Part B top-line timing guidance by year-end 2026, DNTH212 Phase 1 healthy-volunteer data by year-end 2026, and EMERGE top-line results in 2H 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Dianthus Therapeutics reported a net loss of $40.8 million for Q1 2026, a significant increase from the $29.5 million loss in Q1 2025, driven by a 28% rise in R&D expenses to $34.5 million due to heightened clinical…
- 10-K · March 9, 2026
- Dianthus (DNTH) is a clinical‑stage biotech focused on next‑generation complement and bifunctional immunology candidates (lead: claseprubart; second: DNTH212). The 10‑K highlights positive Phase 2 MaGic data (65…
- 10-Q · November 5, 2025
- Dianthus reported Q3 revenue of $396,000 (three months ended September 30, 2025) versus $2,172,000 in Q3 2024, a sharp decline. The company’s loss widened to $36,765,000 for the quarter (net loss per share $0.97) versus…
- 10-Q · August 7, 2025
- Dianthus reported a steep revenue decline to $193,000 in Q2 2025 and a widening loss as R&D and G&A spending ramped. Net loss for the quarter was $31.6 million (EPS -$0.88), cash and cash equivalents declined to $13.2…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DNTH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever